Additional file 1: of Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer

Ricciuti, Biagio; Kravets, Sasha; Dahlberg, Suzanne; Umeton, Renato; Albayrak, Adem; Subegdjo, Safiya; Johnson, Bruce; Nishino, Mizuki; Sholl, Lynette; Awad, Mark

doi:10.6084/m9.figshare.7915241.v1

40425_2019_572_MOESM1_ESM.docx (81.55 kB)

Additional file 1: of Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer

journal contribution

posted on 2019-03-28, 05:00 authored by Biagio Ricciuti, Sasha Kravets, Suzanne Dahlberg, Renato Umeton, Adem Albayrak, Safiya Subegdjo, Bruce Johnson, Mizuki Nishino, Lynette Sholl, Mark Awad

Figure S1. Diagram of patients with SCLC who underwent successful next generation sequencing who either did or did not receive treatment with immune checkpoint inhibitors. Patients who never received any systemic therapy for their disease are indicated. (DOCX 81 kb)